Division of Pharmacy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.
Department of Pharmacy, Michigan Medicine, 1500 E. Medical Center Dr., Ann Arbor, MI 48109, USA.
J Antimicrob Chemother. 2017 Dec 1;72(12):3232-3244. doi: 10.1093/jac/dkx266.
Although new antimicrobial stewardship programmes (ASPs) often begin by targeting the reduction of antimicrobial use, an increasing focus of ASPs is to improve the management of specific infectious diseases. Disease-based antimicrobial stewardship emphasizes improving patient outcomes by optimizing antimicrobial use and increasing compliance with performance measures. Directing efforts towards the comprehensive management of specific infections allows ASPs to promote the shift in healthcare towards improving quality, safety and patient outcome metrics for specific diseases. This review evaluates published active and passive disease-based antimicrobial stewardship interventions and their impact on antimicrobial use and associated patient outcomes for patients with pneumonia, acute bacterial skin and skin structure infections, bloodstream infections, urinary tract infections, asymptomatic bacteriuria, Clostridium difficile infection and intra-abdominal infections. Current literature suggests that disease-based antimicrobial stewardship effects on medical management and patient outcomes vary based on infectious disease syndrome, resource availability and intervention type.
尽管新的抗菌药物管理计划(ASPs)通常以减少抗菌药物的使用为目标,但 ASP 的重点越来越多地是改善特定传染病的管理。基于疾病的抗菌药物管理通过优化抗菌药物的使用和提高与性能指标相关的合规性,着重于改善患者的结局。将努力集中于对特定感染的全面管理,使 ASP 能够推动医疗保健朝着改善特定疾病的质量、安全性和患者结局指标的方向转变。本综述评估了已发表的主动和被动基于疾病的抗菌药物管理干预措施及其对肺炎、急性细菌性皮肤和皮肤结构感染、血流感染、尿路感染、无症状菌尿、艰难梭菌感染和腹腔内感染患者的抗菌药物使用和相关患者结局的影响。现有文献表明,基于疾病的抗菌药物管理对医疗管理和患者结局的影响取决于传染病综合征、资源可用性和干预类型。